LCD-DL40048
Document details
Summary
The proposed LCD for Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) could have significant billing implications, particularly for allergists and practices specializing in immunothChanges to AIT and SCIT billing may be on the horizon.
Affected specialty
Allergy/Immunology alerts →Source document
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=40047&ver=6CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy LCD-DL40050 · Allergy/Immunology
The proposed Local Coverage Determination (LCD) on Allergen Immunotherapy may impact billing practices for providers offering subcutaneous immunotherapy. It could lead to higher reimbursement rates fo
View alertPolicy LCD-DL40052 · Allergy/Immunology
The proposed LCD for Allergen Immunotherapy may significantly influence billing practices related to Subcutaneous Immunotherapy. Providers will need to ensure proper documentation and coding align wit
View alertPolicy LCD-DL39314 · Allergy/Immunology
The proposed LCD addresses the billing implications for off-label uses of IVIG, which may affect reimbursement rates and eligibility for coverage under Medicare. Providers need to stay informed about
View alertPolicy LCD-DL36408 · Allergy/Immunology
The proposed Local Coverage Determination (LCD) for Allergen Immunotherapy with Subcutaneous Immunotherapy requires billing team review, particularly in allergy-focused practices
View alert